DENTSPLY SIRONA (XRAY) Insider Brian Mckeon Buys $101K of Stock

Brian Mckeon added 10,000 shares of DENTSPLY SIRONA Inc. (XRAY) to his holdings on June 12, 2026. The purchase was made at an average price of $10.12 per share, bringing the total value of the transaction to $101,200. This trade was disclosed in a filing with the Securities and Exchange Commission and represents a direct investment in the dental products manufacturer.

A Wave of Insider Confidence at DENTSPLY SIRONA

This purchase by Mckeon wasn't an isolated event. It coincided with a flurry of activity from other company insiders during the same week in June. On the same day Mckeon made his move, Jonathan Jay Mazelsky also stepped in to buy 10,000 shares at $10.14 each, a trade worth $101,400. Just a few days later, on June 15, 2026, Clyde Hosein purchased 6,500 shares at a price of $9.99 per share. These transactions were not part of pre-arranged 10b5-1 trading plans, which are often used by executives to sell shares at set intervals. Instead, these open-market buys suggest a shared sentiment among leadership as the stock hovered near its annual lows.

DENTSPLY SIRONA Stock Performance

On Tuesday, DENTSPLY SIRONA shares were priced at $10.55. The stock has been trading in a range between $9.36 and $14.76 over the past year. With a market value of about $1.88 billion, the company is currently trading below its 50-day moving average of $11.87 and its 200-day moving average of $11.70. This pricing puts the forward P/E ratio at 6.26, suggesting the market is pricing the stock at a relatively low multiple of its expected future earnings compared to historical norms.

Recent Earnings and Revenue Trends

In its most recent financial disclosures, DENTSPLY SIRONA reported annual revenue of $3.64 billion. However, the company faced some headwinds, with revenue growth down 4.1% and a net margin of -15.0%. The return on equity was also in negative territory at -33.0%. These figures reflect a challenging period for the dental supplier as it navigates shifting demand in its various technology and restorative segments. Investors are looking toward November 5, 2026, when the company is scheduled to release its next set of quarterly results.

Analysts Set New Price Targets

Wall Street firms have been active in adjusting their outlook for XRAY. On October 14, 2026, Leerink Partners maintained a Market Perform rating but lowered its price target to $10.00 from $14.00. Piper Sandler also kept a Neutral rating on October 9, 2026, while trimming its target from $14.00 to $12.00. BMO Capital initiated coverage earlier in the summer with a Market Perform rating and a $12.00 target, later adjusting that target to $10.00 in September. Currently, 16 analysts follow the stock, and the collective recommendation is a Hold.

About DENTSPLY SIRONA Inc.

Based in Charlotte, North Carolina, DENTSPLY SIRONA manufactures a wide range of professional dental products and medical devices. The company is a major player in the dental market, selling everything from 3D imaging equipment and intraoral scanners to root canal tools and clear aligners. It also operates a healthcare division that produces specialized catheters and irrigation systems. The recent insider buying comes at a time when the company is focused on integrating cloud-enabled solutions into its dental equipment lineup.

What's Ahead for DENTSPLY SIRONA Inc.

The cluster of buying by Mckeon and his colleagues will likely keep the stock on the radar of investors who track leadership sentiment. While these insider purchases occurred in mid-June, they serve as a marker of how executives viewed the stock's value during that period. The next major catalyst for the company will be its November earnings report, which will provide more clarity on whether its cost-management efforts and new technology launches are gaining traction.